Now on
Wellcome Trust supports the development of sirolimus in beta- thalassemia, a collaborative project between Rare Partners and Ferrara University
Wellcome Trust supports the development of sirolimus in beta - thalassemia, a collaborative project between Rare Partners and Ferrara University
Orphan Drug Designation for the treatment of sickle cell disease also in USA
Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA
Orphan Drug Designation to sirolimus in Sickle Cell Disease
Orphan Drug Designation to sirolimus in Sickle Cell Disease
Orphan Drug Designation for the use of Teicoplanin in Cystic Fibrosis
The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners
Rare Partners supports the Istituto Italiano di Tecnologia (IIT) for the development of an innovative artificial retina
Rare Partners supports the IIT for the development of an innovative artificial retina